Clinical trialNCT07190469RecruitingPhase 1Interventional

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

SponsorProteinQure Inc.Enrollment80Advanced Solid Tumors CancerTriple Negative Breast Cancer (TNBC)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Philippe Bedard, MD
Recruiting

United States

Md Anderson Cancer Center
Houston, Texas, United States
Timothy A Yap, MBBS, PhD, FRCP
Recruiting
Next Oncology
San Antonio, Texas, United States
David Sommerhalder, MD
Recruiting
Start Mountain Region
West Valley City, Utah, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PQ203

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Sept 2025
Primary completion: 31 Dec 2028
Completion: 28 Feb 2029
Last update posted: 23 Feb 2026
Registered enrollment: 80
Registry id: NCT07190469

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.